PTH and secondary hyperparathyroidism: The relationship between conventional therapy and the risk of developing secondary/tertiary hyperparathyroidism in patients with XLH may be related to a mechanism of secondary hyperparathyroidism caused by oral phosphate in which PTH rises to suppress a temporary increase in serum phosphate levels, resulting in secondary hyperparathyroidism [18].